Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267732 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
A Phase 1 study of Healthy Adult Subjects, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03267732: Completed Phase 1 study of Healthy Adult Subjects, sponsored by Eli Lilly and Company.
NCT03267732 is a Phase 1 study of Healthy Adult Subjects that has completed, run by Eli Lilly and Company. The registered enrollment target is 24 participants, below the 36-participant average among 3 other Healthy Adult Subjects trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03267732, a Phase 1 study of Healthy Adult Subjects, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants.
Primary Outcome
maximal plasma concentration (Cmax)
Conditions Studied
Interventions
- BIOLOGICAL Pegilodecakin
Study Locations (1)
Texas
- PPD Development - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2017-10-30 |
| Phase | Phase 1 |
What the finished NCT03267732 record still lists
NCT03267732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 36-participant average among 3 other Healthy Adult Subjects trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Healthy Adult Subjects appearing as the primary indexed condition, and to 1 intervention - of which Pegilodecakin is the first listed.
NCT03267732 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03267732 about?
NCT03267732 is a clinical study titled "A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)". To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants.
What is the current status of trial NCT03267732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-09-05. Estimated completion is 2017-10-30.
What conditions does trial NCT03267732 study?
This clinical trial studies the following conditions: Healthy Adult Subjects.
What interventions are being tested in trial NCT03267732?
The interventions under investigation include: Pegilodecakin (BIOLOGICAL).
Who is sponsoring clinical trial NCT03267732?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03267732 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI